Piperacillin-tazobactam should be preferred to third-generation cephalosporins to treat wild-type inducible AmpC-producing Enterobacteriaceae in critically ill patients with hospital or ventilator-acquired pneumonia. A propensity score-matched analysis

作者
Cédric Carrié,Guillaume Bardonneau,Laurent Petit,Alexandre Ouattara,Didier Gruson,Bruno Pereira,Matthieu Biais
出处
期刊:Research Square
标识
DOI:10.21203/rs.2.12028/v1
摘要

Abstract BACKGROUND The aim of this study was to compare the rate of therapeutic failure and emergence of resistance in critically ill patients treated by third-generation cephalosporins (3GCs) or piperacillin-tazobactam (PTZ) for wild-type AmpC-producing Enterobacteriaceae pulmonary infections. METHODS In a multicenter retrospective cohort study over a 4-year period, all patients treated for a pulmonary infection related to wild-type AmpC-producing Enterobacteriaceae who received documented antibiotic therapy with 3GCs or PTZ after less than 48 hours of empirical antibiotic therapy were eligible. The main outcome was the rate of therapeutic failure, defined by an impaired clinical response under treatment and/or a relapse of pulmonary infection related to the same pathogen. The secondary outcome was a secondary acquisition of derepressed cephalosporinase-producing Enterobacteriaceae. RESULTS Over the study period, 244 patients were included; 56 (23%) experienced therapeutic failure and 19 (8%) experienced secondary acquisition of resistance. In the non-adjusted cohort, the rate of therapeutic failure and emergence of resistance were significantly higher in the 3GCs group (32 vs. 18%, p = 0.011 and 13 vs. 5%, p = 0.035, respectively). In the propensity score-matched population, the 3GCs group was associated with higher rates of therapeutic failure (HR = 1.61 [1.27 – 2.07]). The secondary de-escalation to 3GCs after 48h of PTZ as a first-line antibiotic therapy was not associated with increased rate of emergence of resistance. CONCLUSION Our study confirms that third-generation cephalosporins should be avoided as first-line antibiotic therapy in wild-type AmpC-producing Enterobacteriaceae pulmonary infections.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
幽默小鸽子完成签到,获得积分10
1秒前
天天向上的应助被豆豆采纳,获得10
1秒前
和信完成签到 ,获得积分10
1秒前
2秒前
wwwteng呀发布了新的文献求助10
2秒前
s_yu完成签到,获得积分10
2秒前
杨自强完成签到,获得积分10
2秒前
孤独的青曼完成签到,获得积分20
2秒前
2秒前
3秒前
风吹麦浪的应助被李亚楠采纳,获得10
3秒前
嵩嵩常安完成签到 ,获得积分10
3秒前
无与伦比完成签到,获得积分10
3秒前
vip_jing完成签到 ,获得积分10
4秒前
慈祥的映阳完成签到 ,获得积分10
4秒前
蜜蜜完成签到,获得积分10
4秒前
简单粗暴导师完成签到,获得积分10
4秒前
lll完成签到,获得积分10
4秒前
4秒前
nianlu完成签到,获得积分10
4秒前
畅快纸飞机完成签到 ,获得积分10
4秒前
小繁完成签到,获得积分10
4秒前
简单山水完成签到,获得积分10
5秒前
TinLi的应助被369ninja采纳,获得10
5秒前
fengqiwu完成签到,获得积分10
5秒前
azzzp发布了新的文献求助10
6秒前
1111完成签到 ,获得积分10
6秒前
林双木完成签到,获得积分10
7秒前
鲸落发布了新的文献求助10
7秒前
7秒前
7秒前
ASBL完成签到,获得积分10
8秒前
迷你的灵阳完成签到,获得积分10
8秒前
Starshine完成签到,获得积分10
9秒前
Dominos完成签到,获得积分10
9秒前
天天向上的应助被hgf采纳,获得10
9秒前
Agnes发布了新的文献求助10
9秒前
徐宇鹏完成签到 ,获得积分10
9秒前
缓慢的冬云完成签到,获得积分0
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180146
求助须知:如何正确求助?哪些是违规求助? 9570319
关于积分的说明 21809739
捐赠科研通 7776294
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479039